Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. [electronic resource]
Producer: 20140926Description: 430-6 p. digitalISSN:- 1532-1827
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biliary Tract Neoplasms -- drug therapy
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Female
- Gallbladder Neoplasms -- drug therapy
- Humans
- Kaplan-Meier Estimate
- Lymphatic Metastasis
- Male
- Middle Aged
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Panitumumab
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins p21(ras)
- Treatment Outcome
- ras Proteins -- genetics
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.